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Abstract
Patient navigation has expanded as a promising approach to improve cancer care coordination and patient
adherence. This paper addresses the need to identify the evidence on the economic impact of patient navigation
in colorectal cancer, following the Health Economic Evaluation Publication Guidelines. Articles indexed in Medline,
Cochrane, CINAHL, and Web of Science between January 2000 and March 2017 were analyzed. We conducted a
systematic review of the literature using Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines. The quality assessment of the included studies was based on the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) checklist. Inclusion criteria indicated that the paper’s subject
had to explicitly address patient navigation in colorectal cancer and the study had to be an economic evaluation.
The search yielded 243 papers, 9 of which were finally included within this review. Seven out of the nine studies
included met standards for high-quality based on CHEERS criteria. Eight concluded that patient navigation
programs were unequivocally cost-effective for the health outcomes of interest. Six studies were cost-effectiveness
analyses. All studies computed the direct costs of the program, which were defined a minima as the program costs.
Eight of the reviewed studies adopted the healthcare system perspective. Direct medical costs were usually divided
into outpatient and inpatient visits, tests, and diagnostics. Effectiveness outcomes were mainly assessed through
screening adherence, quality of life and time to diagnostic resolution. Given these outcomes, more economic
research is needed for patient navigation during cancer treatment and survivorship as well as for patient navigation
for other cancer types so that decision makers better understand costs and benefits for heterogeneous patient
navigation programs.
Keywords: Colorectal cancer , Patient navigation , Cost-benefit analysis , Health care costs
Introduction
The impacts of cancer on individuals, caregivers, society
and health care systems are profound. The National Cancer
Institute estimates that in 2016, 1.6 million people in the
United States will be diagnosed with cancer and nearly
600,000 will die from the disease [1]. Globally, over eight
million lives lost and almost 200 million disability-adjusted
life years were attributed to cancer in 2013 [2]. Close to
$125 billion was spent on cancer care in the U.S. in 2010
[1], a figure anticipated to reach $173 billion by 2020 [3].
The growing cost of cancer care reflects successes in the
field, such as increases in both the percentage of people
who survive cancer and the number of years survived, with
resultant costs of specialized care needs [4]. It also reflects
failures: for example, inadequate coordination of care
through an “increasingly specialized and fragmented health
care system” [5], which can lead to service duplications,
lower treatment adherence, poorer care quality, worse
health outcomes, and increased costs for patients and
payers [6–8].
Cancer cost must be considered in the context of health
and health care disparities. Racial/ethnic minorities,
low-income populations, and others from historically mar-
ginalized backgrounds tend to be diagnosed at later stages
of disease progression, receive lower quality care and bear
* Correspondence: chloegerves@gmail.com
1Research Institute for Environmental and Occupational Health (Irset-Inserm
UMR1085), Ester Team – UFR Santé – Département de Médecine, Rue Haute
de Reculée, 49045 ANGERS Cedex01, France
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Gervès-Pinquié et al. Health Economics Review  (2018) 8:12 
https://doi.org/10.1186/s13561-018-0196-4
a disproportionate burden of disease. Racial/ethnic dispar-
ities in cancer cost an estimated annual $193 billion in
premature death and $471.5 million in lost productivity in
the United States alone [9]. As others have observed, there
are both economic and moral arguments for bending the
cost curve of cancer care [10]. Patient navigation (PN) has
rapidly expanded as a promising approach to address can-
cer disparities, reduce the overall cost of cancer, and im-
prove care coordination and patient adherence across the
care continuum, particularly among minority and/or eco-
nomically disadvantaged patient populations [11, 12].
PN programs have been effective in improving clinical
outcomes and patient experience, including reducing pa-
tient distress and anxiety, shortening acute hospital
stays, increasing patient satisfaction and empowerment,
and reducing disparities in timely movement through
the cancer care trajectory [13]. Yet PN’s effects on the
cost of cancer care are not as well documented. Few
studies on PN programs provide an exhaustive economic
evaluation of their outcomes, and even fewer base their
evaluation on validated methodological guidelines like
the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) and on well-defined coordination
problems [14]. More rigorous economic analyses of PN
are needed for a variety of reasons, not least to inform
policy decisions about if and how to pay for PN services,
which in the U.S. are currently not reimbursed by third
party payers.
Strengthening understanding of the economic impacts
of PN is particularly valuable for cancer types in which
population-level early detection is cost-effective and PN
improves adherence to initial phases of care. Colorectal
cancer (CRC) is the third most commonly diagnosed
cancer in the United States and worldwide. CRC will be
diagnosed in an estimated 96,000 people in the United
States in 2017 and will take the lives of over 50,000 people,
disproportionately affecting racial/ethnic minorities and
economically disadvantaged people due to later-stage
diagnosis and low screening adherence [15]. Globally, al-
most 694,000 lives were lost to CRC in 2012 [2]; it is esti-
mated that worldwide CRC diagnoses will nearly double
in the next two decades to reach 2.4 million cases in 2035.
The United States will spend approximately $17.41 billion
on CRC care in 2020, with over half of cost spent on con-
tinuing care and in the last year of life [3]. Yet, the major-
ity of spending on treatment, as well as the estimated $4.2
billion in productivity lost to CRC deaths and inestimable
individual and family suffering [16], is largely considered
avoidable due to the success of screening and removal of
pre-cancerous polyps.
PN has demonstrated improvements in timely move-
ment through the CRC care trajectory, particularly among
racial/ethnic minority, low-income, and other disadvan-
taged populations [17]. Accordingly, it makes an excellent
case study to examine the economic impacts of PN on
care.
Our study aimed to analyze the literature and assess
the level of evidence on the economic evaluation of PN
programs in CRC.
Methods
Review process
A systematic search of the scientific literature was
conducted in four major databases (MEDLINE using
PubMed, Web of Science, Cochrane and CINAHL) to
identify relevant English-language publications relating
to economic evaluations of PN programs in CRC. The
Preferred Reporting Items for Systematic Review and
Meta-Analysis (PRISMA) guidelines were used to ensure
systematic selection of studies [18] (see Additional file 1:
Table A).
The three preconditions for inclusion were that the
study:
(1) evaluated PN services: we confirmed that each
article explicitly addressed PN (including navigators
with and without a clinical license such as nurses
and social workers performing navigator functions)
rather than other health care provider roles that
may perform similar tasks,
(2) conducted an economic evaluation, and
(3) focused on CRC.
Keywords were defined according to population, inter-
vention/comparator, outcomes, study design elements
(see Additional file 1: Table B). Keywords were searched
in the title or abstract of full-length publications that
were published between January 2000 and march 2017.
Articles were excluded if they did not correspond to
the above criteria. Systematic literature reviews were also
excluded
Study selection
Our initial search resulted in 243 articles that met the
above-mentioned criteria. The retrieved studies were
reviewed by four researchers in close consultation with a
senior author (MPC) and, in case of disagreement, issues
were resolved by consensus.
Duplicates were removed, resulting in a total of 121
articles for review. The 121 citations were screened on
the basis of titles and abstracts. 16 papers were then
selected.
The full-text articles for the 16 abstracts selected for
inclusion were retrieved and read. The final number of
original empirical studies was 9 after assessment of eligi-
bility for inclusion.
Data was extracted independently by four researchers.
Extracted information included: bibliographic details,
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information on participants, PN interventions, out-
comes, study design, and results. Disagreements were re-
solved by discussion.
Figure 1 provides a PRISMA diagram illustrating de-
tails of the search strategy.
Quality assessment
The studies identified for inclusion were assessed against
the 24 key criteria contained in the CHEERS checklist
[19]. The checklist has been jointly endorsed by ten jour-
nals. All items were presented in the tables for this review,
consisting of five broad categories: Title and abstract
(2 items); Introduction (1 item); Methods (14 items);
Results (4 items) and Discussion (3 items) (see
Additional file 1: Table C).
In certain studies, we considered that some CHEERS’
items were not applicable:
– When the time horizon was less than one year,
discounting (item 9) was considered not applicable
– When the economic evaluation was a cost analysis,
effectiveness measurement (item 11) was considered
not applicable
– When measured outcomes were not preference-
based, preference measurement (item 12) was con-
sidered not applicable.
We used the results of the quality assessment for de-
scriptive purposes and to investigate potential sources of
heterogeneity.
Cost classification used
The costs considered were:
– Direct costs encompass all the health care
expenditures generated by the program. They
include the resources used for program
implementation (program cost) and both the
medical and non-medical resources generated as a
consequence of the program (e.g., physician consulta-
tions, treatment cost, professional home care). These
resources are priced on the health care market
(consultation cost, treatment cost, etc.).
– Indirect costs correspond to resources without a
market price, such as opportunity costs for both
the patient (e.g., travel time, waiting time, and
productivity loss on the labor market) and his/her
relatives (since informal care time means the
caregiver cannot pursue other activities). While
necessarily estimated, these resources are given a
monetary value to be integrated within the costs of
the economic evaluation.
Results
We present in Additional file 1: Table C the quality as-
sessment of the included studies based on the CHEERS
checklist. It shows that seven out of the nine studies
reviewed can be considered high quality studies, following
an existing approach to determining quality in cancer
scholarship [20], with an average proportion of 84.8% of
checklist criteria fulfilled.
Table 1 shows the main characteristics of the studies in-
cluded [21–29]. Most articles (n = 6) exclusively addressed
navigating those due for recommended CRC screening to
receive those services (n = 6). The few articles examining
PN to diagnostic resolution (n = 2) addressed multiple
cancer types. Two studies compared PN to screening col-
onoscopy versus other screening modalities (fecal occult
blood testing (FOBT) or fecal immunochemical testing
(FIT)). All studies but one occurred in the United States
and took place in various clinical settings, primarily in the
health care safety net setting. At least two-thirds of studies
focused on racial/ethnic minority, low-income, or other-
wise underserved populations. The only study to address
PN from confirmed diagnosis through treatment or end of
life occurred in New Zealand.
Navigator profiles and roles described in the articles
were diverse. Three studies used nurse navigators; four
used non-clinically licensed navigators with various titles
such as “lay” health educator or outreach worker. One art-
icle included a licensed clinical social worker and at least
two employed bilingual staff. For the seven studies that
described navigator actions, navigators provided assistance
through a wide range of tasks. These included identifica-
tion and removal of barriers to care, coordination of
appointments and referrals, appointment reminders, sup-
port and encouragement, information and education, and
tracking and follow up. Among the reviewed studies, four
were based on randomized controlled trials (RCTs). All
the studies reviewed indicated the time horizon for
evaluation.
243 abstracts identified via 
literature search
16 full-text articles reviewed
9 articles included for 
review
122 abstracts identified via 
literature search
121 articles excluded after 
removing duplicates
106 articles excluded after title 
and abstract search
7 articles did not meet eligibility 
criteria
Fig. 1 Search flow
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Table 2 shows that most of the studies (n = 8) adopted
the health care system perspective, which refers to a var-
iety of entities including the hospital (n = 3) or public or
private payers (n = 5). Six studies were presented as
cost-effectiveness analyses (among which, one presented
both a cost-effectiveness analysis and a cost-benefit ana-
lysis), one was presented as a cost-utility analysis, one
was a cost-consequence analysis, and one was a cost
analysis. If we assume that using Quality Adjusted Life
years (QALYs) implies conducting a cost-utility analysis
[30], two of the cost-effectiveness analysis reviewed were
also cost-utility analyses.
All studies computed the direct costs of the program,
which were defined a minima as the program costs, in-
cluding training, personnel, and supply costs. Eight stud-
ies considered direct medical costs, which were usually
divided into outpatient and inpatient visits, tests and
diagnostics. Estimated treatment cost was only consid-
ered in four papers and no study included direct
non-medical cost, such as home care expenses. Only
one study included indirect costs in the total costs asso-
ciated with the PN program, including patient product-
ivity loss and travel cost. No study included indirect
costs associated with informal care. The clinical out-
comes studied were mainly measures of time from ab-
normal finding to diagnostic resolution (n = 2), receipt of
colonoscopy (n = 4), Quality Adjusted Life Years (n = 3)
or Life years (n = 1). One third of the studies interpreted
their results in relation to different stakeholders’ willing-
ness to pay (WTP) for improvements in care.
All but one study concluded that PN programs were
unequivocally cost-effective for the health outcomes of
interest. For instance, Incremental Cost Effectiveness
Ratios (ICERs) ranged from $65 to $1958 per additional
screening meaning that adopting the PN program
instead of the alternative care strategy considered (for
instance usual care, or fecal occult blood test or auto-
mated electronic health record-linked mailings) leads
to a cost of $[65 to 1958] for an additional screened pa-
tient. ICERs ranged from $1192 to $9708 per diagnostic
resolution and from $3765 to $15,600 per QALY gained.
There was high probability for PN to be cost-effective for
CRC if stakeholder’s WTP ranged between $1200 and
$1697 per additional screening and from $16,500 to
$21,000 per QALY gained. In comparison, the National In-
stitute for Health and Clinical Excellence (NICE) has been
using a cost-effectiveness threshold ranging between
£20,000 and £30,000 ($27,000 – $40,000) – usually per
QALY gained - for over 14 years [31, 32]. The remaining
study concluded that PN programs were only likely to be
cost-effective (at $43,520 per life-year saved) under the
most favorable assumptions, in which patients lost to
follow-up have more advanced cancer, and navigators ac-
count for a 6-month earlier time to diagnostic resolution
and have a 15% higher probability of follow up resolution
completion [24].
Conclusions
Most PN programs for CRC presented in our review had
high probability for being cost-effective compared to usual
care, given a conservative cost-effectiveness threshold of
$50,000 per QALY gained [33]; one study found one-time
PN to be cost- saving. Cost-effectiveness evidence is most
robust for PN programs designed to increase adherence
with CRC screening using colonoscopy. Given the U.S.
Preventive Services Task Force’s A grade recommendation
of CRC screening and the demonstrated success of PN to
increase screening adherence among racial/ethnic minor-
ities, low-income populations, and other disadvantaged
patients, the volume and strength of the evidence in favor
of the economic value of PN for colorectal screening ad-
herence is unsurprising.
There are fewer articles for other phases of the con-
tinuum or using other screening methods [34]. The
scant evidence seems to be tentatively favorable for the
phase from abnormal screening to diagnostic resolution.
Donaldson et al. (2012) concluded that PN programs in-
creased achievement of timely diagnostic resolution for
CRC (as well as breast cancers) among largely uninsured
patients, and would be cost-saving if they were able to
avert three to four cancer deaths per year [21]. Bensink et
al. (2014) found limited economic benefit for PN during
this phase (across four cancer types), indicating the great-
est cost-effectiveness for those with the greatest needs
such as the longest lapses in follow-up after screening, the
most severe screening results, or the greatest potential to
make gains in timeliness [24]. Lairson et al. advised payers
to consider covering the costs of patient navigation for
colonoscopy, which, compared to FOBT, has more chance
to be considered cost-effective and even cost-saving when
adopting larger time horizons [25]. The only study exam-
ining PN during the treatment phase addressed stage III
colon cancer patients. Blakely et al. found PN to have high
probability of cost-effectiveness, even considering a con-
servative WTP threshold [26]. These findings provide
initial promising evidence for decision makers in support
of PN for patients with more advanced cancers, and also
for PN roles in providing treatment coordination and
support.
Evidence of PN’s cost-effectiveness is bolstered by the
methodological soundness of the studies included in this
review. Seven studies, all published after 2012, meet
standards for high-quality based on CHEERS criteria.
One of the studies was a cost analysis, making an incre-
mental interpretation of the results impossible according
to CHEERS guidelines [23].
Although there have been calls for establishing com-
mon PN cost measures [35], establishing such measures
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are challenging since costs to one stakeholder is revenue
for another. In the studies we reviewed, there were varia-
tions in considerations and definitions of direct costs,
indirect costs and health outcomes. The lion’s share of
the total cost of PN programs was most often attributable
to direct medical costs rather than direct non-medical
costs or indirect costs not covered by health insurance
[36]. In other words, most of the reviewed studies adopted
the health care system perspective rather than society’s
perspective.
Only a third of the articles addressed stakeholders’
WTP. WTP is an important consideration to help payers
optimize resource allocation, in particular with PN pro-
grams that are more costly but also more effective [28].
The perspective adopted is also crucial to a discussion of
WTP thresholds, especially since PN programs consid-
ered to be cost-effective for society may exceed a hos-
pital administrator’s budget constraint, or their WTP,
corresponding to their preferences for an improvement
in patient’s health outcome thanks to PN. It is note-
worthy that patient preferences and patient reported
outcomes (PROs) associated with PN are not addressed
in the studies reviewed.
While this review advances understanding of the
cost-effectiveness of CRC PN, findings should be inter-
preted with caution given limitations to current extant re-
search. The heterogeneity of PN programs impedes the
generalizability and comparability of individual and aggre-
gate findings. The diversity of navigator roles, modes of
communication and intensity of the interventions not only
have the potential to produce heterogeneity in PN out-
comes; it also produces variation in direct costs related to
personnel and program costs. In settings in which PN oc-
curs within a multi-faceted approach isolating PN-specific
outcomes from aggregate outcomes may be especially
challenging [23, 35]. For instance, the intervention de-
scribed by Wilson and Villarreal to increase colonoscopy
adherence includes free colonoscopies, extended clinic
hours, and taxi services [29]. Another problem affecting
the generalizability of the results is the definition of usual
care which was appreciably different across the studies
reviewed. Further research could consist in comparing PN
programs by navigator profile in addition to (or even in-
stead of) being limited to a specific pathology. This kind
of comparison would require detailed characteristics about
navigator profile, such as their academic background, pro-
fessional training, level of remuneration, length of work
experience, etc. that are missing in most of the studies
reviewed.
While PN program implementation is characterized by
significant variability, the screening method and phases
of the cancer continuum studied were limited among
the studies examined. Therefore, these cost-effectiveness
evaluation results may not apply for PN interventions
with screening methods and at cancer continuum phases
not included in this review. Extrapolation of findings for
PN cost-effectiveness for other types of cancers should
be done with extreme caution given that colonoscopy
screening doubles as a preventive procedure, extending
savings of early detection and removal of polyps over a
lifetime. Colonoscopy is thus unique among cancer
screening modalities.
Finally, our review faced several of the challenges often
found in economic reviews. Economic modeling is
complex. Multiple different models were used across the
studies included in review, and results could have been
affected by each model’s type, structure, data sources and
assumptions [37]. Lack of cost-benefit analyses prevented
us from assessing whether PN could be profitable for pro-
viders, health care systems and societies (and at what cost
for payers and possibly patients), but such analyses could
move scholarship beyond cost-effectiveness.
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